Objective: To review chromosome 1p/19q lack of heterozygosity (LOH) and Sox17 protein expression in oligodendrogliomas and correlate this loss with clinicopathological features. 3rd party prognostic elements of oligodendrogliomas. Summary: With this research, oligodendroglioma individuals with 1p/19q LOH and Sox17 proteins manifestation had an Duloxetine manufacturer improved prognosis. Thus, evaluation of 1p/19q LOH and Sox17 proteins manifestation could significantly enhance diagnostic accuracy, guide treatment, and improve the prognosis. = 0.102, Table 1). Open in a separate window Physique 1 Deletions in chromosome 1p/19q in oligodendrogliomas. A: 1p deletion with two green (1q) and one red Duloxetine manufacturer (1p) signal in most nuclei. B: 19q deletion with one red (19q) and two green (19p) signals. Open in a separate window Physique 2 A: Normal chromosome 1 with two green and two red signals. B: Normal chromosome 19 with two green and two red signals. Table 1 Effects of genetic factors on 1p/19q and Sox17 protein expression Rabbit Polyclonal to VEGFR1 in oligodendrogliomas = 0.026, Table 1). Open in a separate window Physique 3 A: Expression of Sox17 protein in the cytoplasm of oligodendrogliomas (EnVision 40 10. B: Sox17 protein expression in the nucleus of oligodendrogliomas (EnVision 40 10). Open in a separate Duloxetine manufacturer window Physique 4 The relationship between survival time after surgery and the presence of 1p/19q in oligodendrogliomas. Correlation analysis of 1p/19q co-deletion and Sox17 expression in oligodendrogliomas by Spearmans rank correlation test showed a significant positive correlation (r = 0.521, P = 0.521). Correlation of 1p/19q Duloxetine manufacturer co-deletion and Sox17 expression with clinicopathological parameters As shown in Table 2, the prevalence of 1p/19q co-deletion and Sox17 expression was higher among younger adults 18 to 60 years of age when compared to older adults 60 years of age in juveniles; this difference was significant for oligodendrogliomas (= 0.000). A 1p/19q co-deletion in a frontal, temporal location was more frequent than in other locations (= 0.050). However, there was no significant relationship between 1p/19q co-deletion and gender, ethnic group or between expression of Sox17 and gender, ethnic group, or location. Table 2 Correlations of 1p/19q co-deletion and Sox17 expression with clinicopathological parameters in oligodendrogliomas = 0.000) Sox17 expression (Figure 5, = 0.000), chemotherapy (= 0.000) and radiation therapy (= 0.001) were related to patient survival time, while histologic subtype (= 0.214), patient age (= 0.297), ethnicity (= 0.583), and gender (= 0.783) were not. Cox multiple factors regression analysis further decided that 1p/19q co-deletion and Sox17 expression were impartial prognostic factors of oligodendrogliomas. Open in a separate window Physique 5 The relationship between survival time after surgery and the expression of Sox17 in oligodendrogliomas. Discussion Oligodendrogliomas occur in the cerebral cortex; 50% are reported in the frontal lobe and the remaining 50% in the parietal and temporal lobes [1]. In recent years, great progress has been made in our understanding of the molecular biology of gliomas. Which can be used to improve the diagnosis, prognosis and provide evidence for the selection of targeted therapy. In the present study, the co-deletion of chromosomes 1p/19q was a common feature of oligodendrogliomas. Ranghavan et al. reported that oligodendrogliomas with a co-deletion of 1p/19q in older children tended to have a greater overlap with their adult counterparts, and patients 60 years of age had significantly fewer co-deletions of 1p/19q than younger patients [6,7]. These results are consistent with our observations. This demonstrates that 1p/19q LOH is not a distinct molecular alteration in children and older patients. Age is likely an important factor influencing molecular genetic abnormalities of oligodendrogliomas due to the presence of distinct pathogenetic pathways in the genesis of these oligodendrogliomas or reduced tumor suppressor gene deactivation due to 1p/19q LOH. We correlated 1p/19q LOH with tumor location and found results similar to prior reports [8-11], in terms of a positive association between 1p/19q LOH and tumor location. Frontal and parietal lobe oligodendrogliomas have more frequent 1p/19q co-deletions than their morphologically indistinguishable counterparts in other lobes. Simultaneously, tumor sites in these lobes were more responsive to chemotherapy than those in other lobes, and patients had better outcomes [12]. We suspect that this distinction may be because of the.